Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

Key Points

Key points are not available for this paper at this time.

Abstract

An uncomplicated, widely available, prophylactic regimen (COCOON DM) reduced the incidence of DAEIs with amivantamab-lazertinib and the impact of symptoms on QoL.

Perguntar à IA

Bookmark

View Full Paper

Perguntar à IA

Bookmark

View Full Paper

Cite This Study

Cho et al. (Tue,) studied this question.

synapsesocial.com/papers/69d76c03ef4aa71f97f314b5 https://doi.org/https://doi.org/10.1016/j.jtho.2025.07.117

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Risk of Venous Thromboembolism in Patients With Stage III and IV Non–Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study2024 · 15 citations